Miroslav Backonja, M.D., Senior Medical Director at Worldwide Clinical Trials, will be presenting two sessions at the American Academy of Pain Medicine (AAPM) Annual Meeting, being held March 16-18, 2017 in Orlando, Florida.
Now in its 33rd year, AAPM brings together clinicians, researchers, and educators in pain medicine to discuss emerging trends and research. Dr. Backonja’s two sessions, titled “Neuropathic Pain: Making the Diagnosis” and “Small Fiber Peripheral Neuropathy: New and Often Missed,” will take place consecutively on Saturday, March 18 from 10:15 to 11:45 a.m.
“I’m honored to be presenting at this year’s AAPM meeting, where I’ll be sharing insights with attendees about small fiber neuropathy and neuropathic pain,” commented Dr. Backonja. “The AAPM meeting presents a great opportunity for the leaders in our field to discuss and exchange ideas on how to improve diagnosis and treatment of acute and chronic pain. Certainly, our collective goal is to improve care of our patients suffering from pain and that should translate into their improved functional pain outcomes and quality of life.”
Dr. Backonja, who is board-certified in both neurology and pain medicine, has more than 100 peer-reviewed publications and serves on the editorial boards for a number of pain journals, including Pain, Pain Medicine, the Journal of Pain, and Clinical Journal of Pain. He was recently named as a leading doctor in pain medicine by Seattle Magazine’s Top Doctors 2017 report, an annual report that ranks the Puget Sound’s most trusted physicians, based on recommendations from 8,700 Seattle-based doctors.
About Worldwide Clinical Trials
Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit Worldwide.com.
SOURCE: Worldwide Clinical Trials